Increased PLA Activity in Individuals at Ultra-high Risk for Psychosis

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 2021 Mar 7

PMID 33677687

Citations 2

Authors

Leda L Talib

Alana C Costa

Helena P G Joaquim

Cicero A C Pereira

Martinus T van de Bilt

Alexandre A Loch

Wagner F Gattaz

Affiliations

Soon will be listed here.

Abstract

Phospholipase A is the main enzyme in the metabolism of membrane phospholipids. It comprises a family of enzymes divided into iPLA, cPLA and sPLA. Studies have reported increased PLA activity in psychotic patients, which suggests an accelerated breakdown of membrane phospholipids. In the present study we investigated whether increased PLA activity is also present in individuals at ultra-high risk (UHR) for psychosis. One-hundred fifty adults were included in this study (85 UHR and 65 controls). UHR was assessed using the "structured interview for prodromal syndromes". PLA activity was determined in platelets by a radio-enzymatic assay. We found in UHR individuals increased activities of iPLA (p < 0.001) and cPLA (p = 0.012) as compared to controls. No correlations were found between socio-demographic and clinical parameters and PLA activity. Our findings suggest that increased PLA activities may be useful as a biological risk-marker for psychotic disorders.

Citing Articles

Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder.

Costa A, Rica L, Van De Bilt M, Zandonadi F, Gattaz W, Talib L Metabolites. 2023; 13(5).

PMID: 37233641 PMC: 10222421. DOI: 10.3390/metabo13050600.

Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship.

Yu Y, Su H, Lin S, Hsiao P, Lin Y, Liu C Schizophrenia (Heidelb). 2022; 8(1):38.

PMID: 35853900 PMC: 9261101. DOI: 10.1038/s41537-022-00252-w.

References

Dennis E, Cao J, Hsu Y, Magrioti V, Kokotos G . Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011; 111(10):6130-85. PMC: 3196595. DOI: 10.1021/cr200085w. View

Schaloske R, Dennis E . The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006; 1761(11):1246-59. DOI: 10.1016/j.bbalip.2006.07.011. View

Gattaz W, Kollisch M, Thuren T, Virtanen J, Kinnunen P . Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987; 22(4):421-6. DOI: 10.1016/0006-3223(87)90164-8. View

Gattaz W, Hubner C, Nevalainen T, Thuren T, Kinnunen P . Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatry. 1990; 28(6):495-501. View

Pettegrew J, Keshavan M, Panchalingam K, Strychor S, Kaplan D, Tretta M . Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991; 48(6):563-8. DOI: 10.1001/archpsyc.1991.01810300075011. View

Fenton W, Hibbeln J, Knable M . Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000; 47(1):8-21. DOI: 10.1016/s0006-3223(99)00092-x. View

Emsley R, Oosthuizen P, van Rensburg S . Clinical potential of omega-3 fatty acids in the treatment of schizophrenia. CNS Drugs. 2003; 17(15):1081-91. DOI: 10.2165/00023210-200317150-00003. View

Berger G, Smesny S, Amminger G . Bioactive lipids in schizophrenia. Int Rev Psychiatry. 2006; 18(2):85-98. DOI: 10.1080/09540260600583072. View

Law M, Cotton R, Berger G . The role of phospholipases A2 in schizophrenia. Mol Psychiatry. 2006; 11(6):547-56. DOI: 10.1038/sj.mp.4001819. View

11.

Yung A, McGorry P . The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996; 22(2):353-70. DOI: 10.1093/schbul/22.2.353. View

12.

McGorry P, Hartmann J, Spooner R, Nelson B . Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018; 17(2):133-142. PMC: 5980504. DOI: 10.1002/wps.20514. View

13.

Yung A, Nelson B, Stanford C, Simmons M, Cosgrave E, Killackey E . Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008; 105(1-3):10-7. DOI: 10.1016/j.schres.2008.07.012. View

14.

Loch A, Chianca C, Alves T, Freitas E, Hortencio L, Andrade J . Poverty, low education, and the expression of psychotic-like experiences in the general population of São Paulo, Brazil. Psychiatry Res. 2017; 253:182-188. DOI: 10.1016/j.psychres.2017.03.052. View

15.

Loewy R, Bearden C, Johnson J, Raine A, Cannon T . The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res. 2005; 77(2-3):141-9. DOI: 10.1016/j.schres.2005.03.007. View

16.

Hall R . Global assessment of functioning. A modified scale. Psychosomatics. 1995; 36(3):267-75. DOI: 10.1016/S0033-3182(95)71666-8. View

17.

Loch A, Freitas E, Hortencio L, Chianca C, Alves T, Serpa M . Hearing spirits? Religiosity in individuals at risk for psychosis-Results from the Brazilian SSAPP cohort. Schizophr Res. 2018; 204:353-359. DOI: 10.1016/j.schres.2018.09.020. View

18.

Gattaz W, Schmitt A, Maras A . Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res. 1995; 16(1):1-6. DOI: 10.1016/0920-9964(94)00060-l. View

19.

Ross B, Turenne S, Moszczynska A, Warsh J, Kish S . Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res. 1999; 821(2):407-13. DOI: 10.1016/s0006-8993(99)01123-3. View

21.

Smesny S, Rosburg T, Nenadic I, Fenk K, Kunstmann S, Rzanny R . Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage. 2007; 35(2):729-37. DOI: 10.1016/j.neuroimage.2006.12.023. View

22.

Smesny S, Kunstmann C, Kunstmann S, Willhardt I, Lasch J, Yotter R . Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12. World J Biol Psychiatry. 2010; 12(8):598-607. DOI: 10.3109/15622975.2010.541283. View